Advancing Cardiovascular Risk Identification with Structured Clinical Documentation and Biosignal Derived Phenotypes Synthesis (ACRIBiS) - ACRIBiS Cohort, Heidelberg Site – Module 3: Application of the Medical Informatics Initiative

Advancing Cardiovascular Risk Identification with Structured Clinical Documentation and Biosignal Derived Phenotypes Synthesis (ACRIBiS) - ACRIBiS Cohort, Heidelberg Site – Module 3: Application of the Medical Informatics Initiative - ACRIBiS - Heidelberg

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00039687

Enrollment

500

Registered

2026-04-17

Start date

2025-01-23

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

At least one of the following diagnoses o Diagnosis of manifest arteriosclerotic cardiovascular disease in the medical history as defined below: Acute myocardial infarction (ICD: I21), acute coronary syndrome (ICD: I24), coronary and arterial revascularization (bypass surgery (OPS: 5-361, 5-362), vascular angioplasty (OPS: 8-836.0, 8-36.1, 836. 2)), proven arteriosclerosis in imaging (coronary angiography (OPS: 1-275), arterial ultrasound), stroke (ICD: I63), TIA (ICD: G45.9), aortic aneurysm (I

Interventions

Group 1: Documentation of the structured medical history and documentation of diagnoses, biosignals (automatically analyzed ECG data), therapies, medication as part of the clinical routine. Study-spec

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Previously diagnosed cardiovascular disease

Exclusion criteria

Exclusion criteria: Congenital malformations of the heart

Design outcomes

Primary

Measure	Time frame
Primary endpoints (time point: 12 months after study inclusion): - SMART (Second manifestations of arterial disease) risk score: recurrent cardiovascular event (myocardial infarction, stroke, death due to a cardiovascular event) - CHA2DS2VASc risk score (CHA2DS2-VASc Score calculates stroke risk for patients with atrial fibrillation): Stroke - Barcelona Bio-Heart Failure risk calculator: Re-hospitalization due to heart failure, death	—

Measure

Time frame

Primary endpoints (time point: 12 months after study inclusion): - SMART (Second manifestations of arterial disease) risk score: recurrent cardiovascular event (myocardial infarction, stroke, death due to a cardiovascular event) - CHA2DS2VASc risk score (CHA2DS2-VASc Score calculates stroke risk for patients with atrial fibrillation): Stroke - Barcelona Bio-Heart Failure risk calculator: Re-hospitalization due to heart failure, death

—

Secondary

Measure	Time frame
Secondary endpoints: - PROMIS-29 (Patient Reported Outcomes Measurement Information System) - Quality of life: EQ-5D-5L (Patient Reported Outcome (PRO) instrument 5-level EQ-5D version (EQ-5D-5L) from EuroQol) - Further or extended scores for defined domains (voluntary) - Cardiovascular risk - Incident atrial fibrillation/bleeding events in atrial fibrillation (e.g. CHARGE-AF - prediction of atrial fibrillation, HASBLED - estimation of bleeding tendency in anticoagulated patients with atrial fibrillation) - Rehospitalization/mortality in heart failure (e.g. MAGGIC - Risk Score of the Meta-Analysis Global Group in Chronic Heart Failure) - Mortality (e.g. microfragmentation/polyscore)	—

Measure

Time frame

Secondary endpoints: - PROMIS-29 (Patient Reported Outcomes Measurement Information System) - Quality of life: EQ-5D-5L (Patient Reported Outcome (PRO) instrument 5-level EQ-5D version (EQ-5D-5L) from EuroQol) - Further or extended scores for defined domains (voluntary) - Cardiovascular risk - Incident atrial fibrillation/bleeding events in atrial fibrillation (e.g. CHARGE-AF - prediction of atrial fibrillation, HASBLED - estimation of bleeding tendency in anticoagulated patients with atrial fibrillation) - Rehospitalization/mortality in heart failure (e.g. MAGGIC - Risk Score of the Meta-Analysis Global Group in Chronic Heart Failure) - Mortality (e.g. microfragmentation/polyscore)

—

Countries

Germany

Contacts

Public ContactChristoph Dieterich

Universitätsklinikum Heidelberg

Christoph.Dieterich@med.uni-heidelberg.de+49622156310993

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: May 1, 2026